好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

iPSC Model of CHRFAM7A Effect on a7 Nicotinic Acetylcholine Receptor Function in the Human Context
Aging, Dementia, and Behavioral Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
9-002
The α7 nicotinic acetylcholine receptor (α7nAChR) has been a promising target for neuropsychiatric disorders, however the effect observed in animal models failed to translate into human clinical trials. CHRFAM7A is a human specific fusion gene with properties that enable incorporation into the α7nAChR and its effect was not accounted for in preclinical studies. We hypothesized that CHRFAM7A may account for the translational gap; understanding its function may offer novel insights when exploring α7nAChR as a drug target.

α7nAChRs co-localize with brain regions underlying cognition and memory, are expressed in various cell types, and are the regulators of the cholinergic anti-inflammatory pathway. Amyloid beta 1-42 (Aβ1–42) binds with high affinity to the α7nAChRs, which facilitates internalization of Aβ1–42. A unique feature of the α7nAChR is the presence in different copy number variations and orientation of CHRFAM7A that harbors exons 5-10 of CHRNA7 and 4 exons of the FAM7A.

To study the functional consequences of the presence of the CHRFAM7A, two iPSC lines (0 copy and 1 copy direct) were developed and Medial Ganglionic Eminence progenitors and neurons were generated. As readouts for genotype-phenotype correlation, α7nAChR synaptic transmission and Aβ1–42 uptake were tested.

Synaptic transmission in the presence of CHRFAM7A demonstrated that PNU-modulated desensitization of α7nAChR currents increased as a function of CHRFAM7A dosage. CHRFAM7A mitigated the dose response of Aβ1–42 uptake suggesting a protective effect beyond physiological concentrations. Furthermore, in the presence of CHRFAM7A Aβ1–42 uptake activated neuronal interleukin 1β and TNFα without activating the canonical inflammasome pathway. Preliminary data on potential mechanisms are discussed.

CHRFAM7A modulated α7nAChR and mitigated the dose response of Aβ1–42 uptake, suggesting a protective effect beyond physiological concentrations. Lead optimization may identify more potent molecules when the screen has a model harboring CHRFAM7A.  Incorporating pharmacogenetics into clinical trials may enhance signals. 
Authors/Disclosures
Ivanna Ihnatovych, PhD (SUNY At Buffalo)
PRESENTER
No disclosure on file
No disclosure on file
Aya A. Ouf, MBBS Dr. Ouf has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Kinga Szigeti, MD, PhD (University At Buffalo) No disclosure on file